A Comparison of Blood and Tissue Biomarkers Before and After Nephrectomy in the First-line Setting With Everolimus in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
Price : $35 *
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- Acronyms NEORAD
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
- 12 Sep 2017 Results of an exloratory analysis (n=25) presented at the 42nd European Society for Medical Oncology Congress.
- 18 Aug 2016 Status changed from recruiting to completed.